Low-Dose Naltrexone (LDN)

Low-dose naltrexone (LDN) at a small fraction of the standard dose — off-label for chronic pain, autoimmune conditions, and as a post-acute adjunct. Evidence and caveats.

LDN is the same molecule as normal-dose naltrexone used at roughly 1/10 to 1/50 of the standard dose. At those low doses the behavior is different, it does not produce sustained opioid receptor blockade, and the hypothesized mechanisms involve transient blockade triggering compensatory endogenous opioid system upregulation and (separately) anti-inflammatory effects on microglia. It is prescribed off-label for a range of indications and is gaining attention as an adjunct for post-acute recovery from opioid dependence.

This page is one of three in the naltrexone group on this site. See the parent overview for the comparison across normal-dose, LDN, and ULDN.

Overview

A 2018 narrative review (Toljan & Vrooman, Med Sci) defines the LDN dose range as 1 to 5 mg per day, with the most commonly reported clinical dose being 4.5 mg nightly. A more recent 2025 scoping review of 68 studies (Leiber & Parker, Cureus) confirms 4.5 mg once daily as the dominant protocol, with reported effective ranges from 1 to 6 mg, while noting that large RCTs are still lacking for almost every indication.

The only commercially manufactured naltrexone product is the 50 mg tablet for opioid and alcohol use disorder. LDN at the doses above requires either pill-cutting (imprecise) or, more commonly, a 503A compounding pharmacy that prepares low-dose capsules or liquid suspensions from naltrexone powder.

Hypothesized mechanisms

The mechanism of action at low doses is not fully settled. Two main hypotheses, both with peer-reviewed support but neither established as the complete explanation:

  • Transient mu/delta blockade triggering endorphin upregulation. Brief receptor blockade during the dose’s active window is hypothesized to provoke a compensatory increase in endogenous opioid production and receptor density after the blockade lifts. Reviewed in Younger, Parkitny & McLain (Clin Rheumatol 2014).
  • TLR4 antagonism on microglia. Naltrexone and naloxone act non-stereoselectively as antagonists at toll-like receptor 4 on microglia, suppressing neuroinflammation independent of any opioid receptor activity. The Hutchinson et al. preclinical work (Eur J Neurosci 2008) established this mechanism in rodent models.

The two mechanisms are not mutually exclusive, current LDN researchers generally invoke both. Pages that present a single mechanism as settled (or that present LDN’s mechanism as “definitive”) are getting ahead of the literature.

Evidence base by condition

The published clinical evidence exists but is limited. Pattern: pilot trials, small RCTs, and case series, mostly from single groups, with large multi-site replication still lacking.

Fibromyalgia. Two small trials from the Younger lab, a pilot (n=10, Pain Med 2009) and a crossover RCT (n=31, Arthritis Rheum 2013), showed 28.8% vs. 18.0% pain reduction (p=0.016) with 4.5 mg/day plus improvements in mood and life satisfaction. These are the strongest LDN trials in the literature, and they are still small single-group studies awaiting replication.

Crohn’s disease. An open-label pilot (Smith et al., Am J Gastroenterol 2007, n=17) reported 89% response and 67% remission with 4.5 mg/day; a pediatric pilot (n=14, 2013) supported safety. Both are pilots, not RCTs.

Multiple sclerosis. Gironi (n=40, primary progressive MS, Mult Scler 2008) found LDN safe and well-tolerated with reduced spasticity. A Cree crossover RCT (n=80, Ann Neurol 2010) showed mental-health quality-of-life improvements but high dropout limited statistical power.

Opioid detox enhancement. One RCT, Mannelli et al. (Am J Addict 2009), added very-low-dose naltrexone (0.125–0.25 mg) to a methadone taper and reported attenuated withdrawal and significantly higher early abstinence rates at one week post-discharge. This is one trial. It’s encouraging and it’s the closest peer-reviewed data the LDN-in-recovery use case has, but it is not a deep evidence base.

For 7-OH and kratom synthetics specifically: no published clinical literature. Anecdotal use is common in recovery communities; clinicians prescribing it for this population are extrapolating from the OUD literature above. That should be named plainly rather than dressed up as 7-OH-specific evidence.

Typical use in recovery contexts

Clinical practice, what prescribers using LDN for post-acute recovery do, descriptively:

  • Started after complete opioid clearance, typically 7 to 14 days fully opioid-free per the standard naltrexone-initiation windows (see the normal-dose page for the underlying guidance). For the longer-acting kratom synthetics, longer windows are often used out of caution.
  • Dose-titration over weeks is common rather than starting at the full reported dose immediately. The titration approach and endpoint are set by the prescriber based on response.
  • Often dosed at night because vivid dreams and sleep disruption are documented early side effects; some clinicians switch to morning dosing if sleep doesn’t settle.
  • A compounding pharmacy is required. The LDN Research Trust maintains independent provider and pharmacy directories that some prescribers and patients use as a starting point.

This site does not prescribe doses or schedules. The numbers above come from the cited clinical references; the actual treatment plan sits with a clinician who knows your situation.

Side effects

LDN’s side-effect profile is generally mild, much milder than full-dose naltrexone, but present:

  • Vivid dreams and sleep disruption in the first one to two weeks, often resolving with continued use or a switch to morning dosing (Younger 2009; Toljan & Vrooman 2018 review)
  • Headache, occasional GI upset early on
  • The 2018 review notes side effects are “infrequent and minor” in the reported clinical literature, with serious adverse events uncommon at LDN doses

If you ever need acute pain management while on LDN, tell the provider. Standard opioid analgesics will be partially blocked during the active dose window. Carrying a card or note that identifies you as taking LDN is a reasonable precaution.

Safety, the precipitated-withdrawal caveat

LDN’s precipitated-withdrawal risk is lower than full-dose naltrexone but not zero. The same mechanism (mu-opioid antagonism) applies; the dose is smaller, but if there are still opioids on your receptors when you take LDN, you can still get a withdrawal-like response. This is more likely if the dose creeps up, if the opioid is long-acting (kratom synthetics, methadone, buprenorphine), or if the abstinence window was shorter than the clinical guidelines call for.

The opioid-free windows on the normal-dose page are the right starting reference. LDN initiation still belongs with a clinician, not as DIY.

Boundaries: what LDN is not

  • Not a withdrawal medication. It will make withdrawal worse, not better, if started while opioids are still active. See Withdrawal Help for the four community-documented paths off the synthetics.
  • Not a substitute for MAT or SR-17 during the active quitting phase. LDN comes in after.
  • Not a cure-all. Real evidence in fibromyalgia and some autoimmune conditions; thinner evidence in OUD recovery; almost no 7-OH-specific data. Real but limited.
  • Not ULDN. Ultra-low-dose naltrexone uses microgram doses (about 1,000× smaller), is taken with opioids, and is investigational with thin evidence, completely different protocol with different pharmacology and different risks.

Further reading

Last updated: View source on GitHub